Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The treatment of light-chain (AL) amyloidosis is directed against the plasma cells that produce the light-chain forming the amyloid deposits. The plasma cells can be killed and their growth can be stopped by drugs used in chemotherapy, such as cyclophosphamide, steroids, such as dexamethasone, and drugs that stimulate the immune system, such as lenalidomide.

The present trial studies the efficacy and safety of the combination of cyclophosphamide, lenalidomide and dexamethasone in patients with AL amyloidosis who were previously treated and need further therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

NCT00890552

Leukemia Amyloidosis

COMPLETED NA

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

NCT01194791

Primary Systemic Amyloidosis

COMPLETED PHASE2

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

NCT01728259

Light Chain Deposition Disease Primary Systemic Amyloidosis

TERMINATED PHASE1

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis

NCT00883623

Primary Amyloidosis

COMPLETED PHASE2

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047

AL Amyloidosis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will include previously treated patients with AL amyloidosis.

Primary objectives to determine the hematologic and organ response rate to the association of cyclophosphamide, lenalidomide and dexamethasone (CLD).

Secondary objectives

* to determine the safety of CLD,
* to determine time to response to CLD,
* to determine the duration of response to CLD,
* to assess survival of AL amyloidosis patients treated with CLD.

Patients receive 28-day cycles cyclophosphamide on days 1, 8 and 15, oral lenalidomide on days 1-21 and oral dexamethasone on days 1, 8, 15, and 22.

Up to 9 courses can be performed until one of the following endpoints is met:

* completion of cycle 9,
* complete hematologic remission observed after cycle 3 or 6,
* partial hematologic response associated with organ response after cycle 6.
* no response at cycle 3 or 6. After completion of study treatment, patients are followed every 3 months for up to 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

The participants receive up to 9 28-day cycles of

* cyclophosphamide: 500 mg orally on days 1, 8, 15;
* lenalidomide: 15 mg orally on days 1-21;
* dexamethasone: 40 mg orally on days on days 1, 8, 15, 22.

Group Type EXPERIMENTAL

cyclophosphamide

Intervention Type DRUG

cyclophosphamide: 500 mg orally on days 1, 8, 15

lenalidomide

Intervention Type DRUG

lenalidomide: 15 mg orally on days 1-21

dexamethasone

Intervention Type DRUG

dexamethasone: 40 mg orally on days on days 1, 8, 15, 22

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cyclophosphamide

cyclophosphamide: 500 mg orally on days 1, 8, 15

Intervention Type DRUG

lenalidomide

lenalidomide: 15 mg orally on days 1-21

Intervention Type DRUG

dexamethasone

dexamethasone: 40 mg orally on days on days 1, 8, 15, 22

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Endoxan D003520 Revlimid CC 5013 C467567 Soldesam D003907

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of AL amyloidosis.
* Evidence of a monoclonal light chain at serum and/or urine immunofixation electrophoresis.
* Elevated circulating free light chain (of the type identified by immunofixation) above the upper limit of the normal range and abnormal kappa/lambda ratio.
* Previously treated and requiring further treatment.
* Symptomatic organ involvement.
* Bone marrow plasma cell \<30%.
* Echocardiographic ejection fraction \>40%.
* Troponin I \<0.1 ng/mL.
* Hemoglobin \>10 g/dL.
* Absolute neutrophil count \>1500/uL.
* Platelet count \>140000/uL.
* Total bilirubin \<2.5 mg/dL.
* Alkaline phosphatase \<4 x upper reference limit (u.r.l.).
* ALT \<3 x u.r.l..
* Glomerular filtration rate \>30 mL/min.
* Performance status ECOG 1-3.
* Female subjects of childbearing potential must have two negative pregnancy tests prior to starting study drug.

Exclusion Criteria

* Prior treatment with the association of cyclophosphamide, lenalidomide and dexamethasone or with lenalidomide.
* Requirement for other concomitant chemotherapy, immunotherapy or radiotherapy, or any investigational ancillary therapy.
* Presence of other active malignancies, with the exception of nonmelanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate specific antigen is within normal limits.
* Clinically overt multiple myeloma.
* Uncontrolled infection.
* New York Heart Association (NYHA) class 4 heart failure.
* Enzyme documented myocardial infarction within 6 months before enrollment.
* Grade 2 or 3 atrioventricular block (Mobitz type I is permitted).
* Repetitive ventricular arrhythmias at 24 h Holter electrocardiogram in spite of treatment with amiodarone.
* Supine systolic blood pressure \<90 mmHg, or symptomatic orthostatic hypotension, or a decrease in systolic blood pressure on standing of \>20 mmHg in spite of being treated for orthostatic hypotension.
* Prior history of thrombosis or venous thromboembolism or pulmonary embolism. Prior diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency.
* Indication to receive clopidogrel, ticlopidine or warfarin.
* Factor X level \<20%.
* Poorly controlled diabetes mellitus (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months).
* Previous or ongoing psychiatric illness (with the exclusion of reactive depression).
* Pregnant or nursing women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No